Compare Gemini Space Station Inc (GEMI) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gemini Space Station Inc vs GSK plc — how do they compare? Gemini Space Station Inc trades at $4.42 (market cap $579.55M), while GSK plc trades at $46.52 (market cap $91.88B). The key difference: GSK plc is far larger — about 158.5× Gemini Space Station Inc's market cap, and GSK plc pays a 3.9% dividend while Gemini Space Station Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gemini Space Station Inc for 14 Days and GSK plc for 93 Days on average.
| GEMI | GSK | |
|---|---|---|
Market Cap | $579.55M | $91.88B |
Volume | 1,882,406 | 7,730,529 |
Sector | Financials | Health |
52-Week High | $25.41 | $61.18 |
52-Week Low | $3.54 | $43.24 |
Typical Hold Time | 14 Days | 93 Days |
Enterprise Value | $558.57M | $111.88B |
Dividend Yield | — | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gemini Space Station (GEMI) trades at $4.395, down 2.12% today, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue growth of 37% year-over-year but missed earnings estimates with a net loss of -$0.89 per share. Despite negative profitability margins, analyst consensus price target is $5.25 with 33% buy ratings. Recent news highlights expansion into commission-free stock trading and ongoing securities litigation.
The stock faces significant fundamental challenges with negative profit margins and cash burn, though revenue growth and new business initiatives provide potential catalysts. High volatility and legal risks weigh on investor sentiment, creating a speculative opportunity for those betting on the company's super app strategy amid cautious Wall Street coverage.
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gemini Space Station Inc
Gemini Space Station Inc is the parent company of the Gemini crypto ecosystem, founded by Cameron and Tyler Winklevoss. It operates as a regulated digital asset exchange and custodian, providing a platform for individuals and institutions to trade, store, and stake cryptocurrencies while serving as a trusted bridge between legacy finance and the decentralized web.
Read more on GEMI →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
